Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab Phase 2b in Uncontrolled Asthma
NCT01238861Phase 2Completed
- Sponsor
- MedImmune
- Start
- Dec 2010
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of benralizumab in asthma (6 arms), sponsored by MedImmune. Primary endpoint: Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants at Week 52. Started Dec 2010; status: completed.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01238861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01238861.